BACKGROUND: Confusion exists when dosing heparin using a weight-based nomogram in the obese population. At 2 affiliated community teaching hospitals, we compared the activated partial thromboplastin time (aPTT) values in morbidly obese and nonmorbidly obese patients using a standardized nomogram and determined factors associated with achieving a supratherapeutic aPTT value. METHODS: This was a retrospective study that included patients who had received intravenous heparin according to a standardized weight-based nomogram for >or=12 hours. The exclusion criteria were age <18 years, pregnancy, and insufficient data. Patients were stratified into morbidly obese (body mass index [BMI] >or=40 kg/m(2)) and nonmorbidly obese (BMI <40 kg/m(2)) groups. The aPTT values were compared and predictors for a supratherapeutic aPTT values were identified. RESULTS: A total of 101 patients were included in the study. Greater aPTT values were noted at 6 hours (155 +/- 37 versus 135 +/- 44, P = .020) and 12 hours (141 +/- 45 versus 117 +/- 45, P = .012) for patients with morbid obesity than for those without it, respectively. Increasing BMI (odds ratio = 1.06, 95% confidence interval 1.02-1.1; P = .003) and age (odds ratio 1.05, 95% confidence interval 1.02-.09; P = .001] were independent predictors of supratherapeutic aPTT values. CONCLUSION: Heparin dosing with a weight-based nomogram will yield greater aPTT values in morbidly obese patients. Consideration of BMI and age can help identify those patients at risk of supratherapeutic aPTTs. Alternative strategies, such as a dose cap should be considered in patients with morbid obesity.
BACKGROUND: Confusion exists when dosing heparin using a weight-based nomogram in the obese population. At 2 affiliated community teaching hospitals, we compared the activated partial thromboplastin time (aPTT) values in morbidly obese and nonmorbidly obesepatients using a standardized nomogram and determined factors associated with achieving a supratherapeutic aPTT value. METHODS: This was a retrospective study that included patients who had received intravenous heparin according to a standardized weight-based nomogram for >or=12 hours. The exclusion criteria were age <18 years, pregnancy, and insufficient data. Patients were stratified into morbidly obese (body mass index [BMI] >or=40 kg/m(2)) and nonmorbidly obese (BMI <40 kg/m(2)) groups. The aPTT values were compared and predictors for a supratherapeutic aPTT values were identified. RESULTS: A total of 101 patients were included in the study. Greater aPTT values were noted at 6 hours (155 +/- 37 versus 135 +/- 44, P = .020) and 12 hours (141 +/- 45 versus 117 +/- 45, P = .012) for patients with morbid obesity than for those without it, respectively. Increasing BMI (odds ratio = 1.06, 95% confidence interval 1.02-1.1; P = .003) and age (odds ratio 1.05, 95% confidence interval 1.02-.09; P = .001] were independent predictors of supratherapeutic aPTT values. CONCLUSION:Heparin dosing with a weight-based nomogram will yield greater aPTT values in morbidly obesepatients. Consideration of BMI and age can help identify those patients at risk of supratherapeutic aPTTs. Alternative strategies, such as a dose cap should be considered in patients with morbid obesity.
Authors: Seth R Bauer; Narith N Ou; Benjamin J Dreesman; Jeffrey J Armon; Jan A Anderson; Stephen S Cha; Lance J Oyen Journal: Mayo Clin Proc Date: 2009-12 Impact factor: 7.616
Authors: Anthony T Gerlach; Jerilynn Folino; Benjamin N Morris; Claire V Murphy; Stansilaw P Stawicki; Charles H Cook Journal: Int J Crit Illn Inj Sci Date: 2013-07
Authors: Maureen A Smythe; Jennifer Priziola; Paul P Dobesh; Diane Wirth; Adam Cuker; Ann K Wittkowsky Journal: J Thromb Thrombolysis Date: 2016-01 Impact factor: 2.300
Authors: James W Schurr; Anne-Marie Muske; Craig A Stevens; Sarah E Culbreth; Katelyn W Sylvester; Jean M Connors Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389